AstraZeneca FluMist Supply Jumps With CDC's Seal Of Approval
Executive Summary
US FDA's approval kept very limited amounts available the past two flu seasons; 2.7 million doses to be shipped for the 2018-2019 season.
You may also be interested in...
FluMist Rejuvenated With CDC Advisory Panel Endorsement; Effectiveness Data Still To Come
US panel votes 12 to 2 to recommend use of nasal vaccine, which has been reformulated to include a new influenza A strain.
FDA Supports FluMist Use, Releases Lots For 2016 Flu Season
Despite a CDC advisory committee recommendation that FluMist not be used in the forthcoming influenza season, FDA says the benefits of the nasal formulation outweigh any potential risks.
Pandemic Accelerates US FDA’s Use Of Real-World Data From Clinical Trial Design To Supply Chain
FDA’s Amy Abernethy describes how agency’s use of real-world data has evolved in response to COVID-19 and the ‘a-ha’ moment of leveraging different data sources to understand the coronavirus. Takeda R&D President Andrew Plump notes difficulties with platform trials and limitations on data sharing.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: